Loading company…
NEURACLE SCIENCE develops antibody treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's.
Founded in 2015 and based in Seoul, South Korea, NEURACLE SCIENCE CO. LTD is a biopharmaceutical company. Its pipeline includes NS101, an antibody in clinical development for Alzheimer's disease and other neurodegenerative conditions, and NS200, which targets colonic motility disorders and neurogenic bowel dysfunction. It uses proprietary Fc Engineering to enhance antibody therapeutics. In June 2026 it raised KRW 2 billion in pre-IPO funding from new investor BNH Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in